Pembrolizumab 25 mg/ml

DRUG2 trials

Sponsors

Evaxion Biotech A/S, UNICANCER

Conditions

Melanoma Stage IVTriple-negative Breast CancerUnresectable Melanoma

Phase 2

A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma

Active, not recruitingNCT05309421

Evaxion Biotech A/SMelanoma Stage IV, Unresectable Melanoma

Start: 2022-09-19End: 2026-03-30Updated: 2025-09-22

Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC

RecruitingNCT06078384

UNICANCERTriple-negative Breast Cancer

Start: 2024-12-27End: 2032-01-01Target: 354Updated: 2026-07-24

Related Papers

Abstract 7741: AI-designed personalized neoantigen vaccine, EVX-01, induces durable <i>de novo</i> T-cell responses in advanced melanoma patients

Cancer Research2026-04-03

Abstract P2-10-26: Adjuvant pembrolizumab and chemotherapy or surveillance in Early Triple Negative breAst cancer with high stromal tumor-infiltrating lymphocytes (sTILs) score (ETNA)

Clinical Cancer Research2025-06-13

Abstract 4538: T-cell immunogenicity and biomarker profiling in advanced melanoma patients receiving the personalized vaccine EVX-01 in combination with pembrolizumab

Cancer Research2025-04-21

Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial

Nature Medicine2024-09-1642 citations

Immunogenicity of an AI-designed personalized neoantigen vaccine, EVX-01, in combination with anti-PD-1 therapy in patients with metastatic melanoma.

Journal of Clinical Oncology2024-06-015 citations

782-H Effects of an AI generated personalized neopeptide-based immunotherapy, EVX-01, in combination with pembrolizumab in patients with metastatic melanoma: a clinical trial update

2023-10-311 citations

KEYNOTE – D36: Personalized Immunotherapy with a Neoepitope Vaccine, EVX-01 and Pembrolizumab in Advanced Melanoma

Future Oncology2022-09-0123 citations